On March 1, 2022, Sandoz Canada Inc. (“Sandoz Canada”) announced the completion of the sale of its manufacturing plant to Delpharm, a global drug manufacturer. The plant, located in Boucherville, QC, is the largest sterile injectable production facility in Canada and provides potentially lifesaving medicines to the Canadian and US healthcare systems. While all Sandoz Canada injectable products will be manufactured by Delpharm, Sandoz Canada remains the owner of the marketing authorizations and intellectual property and will continue to have commercial responsibility for all its products.
Sandoz Canada is a pioneer, a leader and trusted supplier of quality generics and biosimilars with over 65 million prescriptions per year, and is the Canadian arm of Sandoz International GmbH, a global leader in generic pharmaceuticals and biosimilars and a division of the Swiss multinational Novartis.
Miller Thomson advised Sandoz Canada with a team led by Louis Clement (Corporate/M&A) and comprised of Julien Morier, Julien Lauzon, Francis Dumoulin (Corporate/M&A); Barbara Farina and Nadim Elkommos (Financial Services); Eric Dufour and Reema Mahbubani (Competition); Lawrence Witt (Employment); Chantal Joubert and Bianka Beaulieu (Real Estate), as well as Martine Bourget (Paralegal).
Freshfields Bruckhaus Deringer LLP advised Sandoz Canada as U.K. counsel, and Delpharm was advised by its French general counsel as well as Gowling WLG as Canadian counsel.
Our Mergers & Acquisitions (M&A) Group is a multi-jurisdictional and multi-disciplinary team of lawyers with experience on all types of domestic and cross-border transactions. With expertise in a wide breadth of industries including Private Equity, Technology, Manufacturing, Healthcare, Life Sciences, and Transportation, we help clients close their business deals efficiently and effectively. Learn more about our full suite of legal services.
